Take the Best Path to Measuring CBL-B and c-CBL Activity

CBL-B and c-CBL are E3-ubiquitin ligases that act as intracellular checkpoints by targeting proteins for degradation via the proteasomal pathway. Targeting CBL-B or c-CBL represents a potential therapeutic strategy for the management of human immune-related disorders such as autoimmune diseases, infections, and cancer. Our two options of CBL-B and c-CBL TR-FRET Assay Kits can measure protein auto-ubiquitination or provide additional insights on polyubiquitination using our Intrachain assay kits.

TR-FRET Assay Kit Advantages

  • Homogeneous assays, ideal for high-throughput applications
  • Available in 384-well plate format
  • All components are included with the kits
  • Use with any plate reader capable of measuring TR-FRET

View the Assay Kits

Knock Down CBL-B with CRISPR/Cas9 Lentiviruses

The CBL-B CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNAs) targeting human CBL-B.

CRISPR/Cas9 Lentivirus

View CBL-B CRISPR/Cas9 Lentiviruses